Sotera Health Company Common Stock vs Sanofi SA — how do they compare? Sotera Health Company Common Stock trades at $17.75 (market cap $5.06B), while Sanofi SA trades at $40.62 (market cap $96.38B). The key difference: Sanofi SA is far larger — about 19× Sotera Health Company Common Stock's market cap, and Sanofi SA pays a 6.08% dividend while Sotera Health Company Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sotera Health Company Common Stock for 0 Days and Sanofi SA for 94 Days on average.
| SHC | SNY | |
|---|---|---|
Market Cap | $5.06B | $96.38B |
Volume | 2,279,715 | 5,335,342 |
Sector | Health | Health |
52-Week High | $19.57 | $52.34 |
52-Week Low | $13.13 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $6.97B | $115.67B |
Dividend Yield | — | 6.08% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sanofi (SNY) trades at $39.12, down 1.56% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with $46.72B revenue, 16.72% net margin, and reasonable valuation (P/E 21.71). Recent expansion of the Regeneron immunology alliance worth up to $8B signals growth potential beyond Dupixent, though 2026 forecasts indicate profit margin compression to 8.09%.
SNY presents a mixed outlook with strong current execution offset by future margin pressures. The bullish analyst consensus (44% Buy) and expanding immunology pipeline provide upside catalysts, while patent expirations and competitive threats pose medium-term risks. Cash flow volatility and debt levels require monitoring for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sotera Health Company is a US provider of sterilization and lab testing services for the healthcare industry, operating through its Sterigenics, Nordion, and Nelson Labs businesses.
Read more on SHC →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →